The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer

Autor: Vivekanandan, S, Landau, DB, Counsell, N, Warren, DR, Khwanda, A, Rosen, SD, Parsons, E, Ngai, Y, Farrelly, L, Hughes, L, Hawkins, MA, Fenwick, JD

Purpose The heart receives high radiation doses during radiation therapy of advanced-stage lung cancer. We have explored associations between overall survival, cardiac radiation doses, and electrocardiographic (ECG) changes in patients treated in IDE

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1032::73f6b28b30ced7f808bce0e26a31a544
http://hdl.handle.net/10044/1/52863

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer.

Autor: Fenwick JD; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Landau DB; Guy's & St. Thomas' NHS Foundation Trust, London, United Kingdom. Electronic address: dblandau@gmail.com., Baker AT; Oxford Cancer Centre, Oxford, United Kingdom., Bates AT; University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom., Eswar C; The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, United Kingdom., Garcia-Alonso A; North Wales Cancer Treatment Centre, Rhyl, United Kingdom., Harden SV; Addenbrookes Hospital, Cambridge, United Kingdom., Illsley MC; Royal Surrey County Hospital NHS Foundation Trust, Guildford, United Kingdom., Laurence V; Poole Hospital NHS Foundation Trust, Poole, United Kingdom., Malik Z; The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, United Kingdom., Mayles WPM; The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, United Kingdom., Miles E; Radiotherapy Trials Quality Assurance Group, Mount Vernon Cancer Centre, Middlesex, United Kingdom., Mohammed N; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom., Spicer J; Guy's & St. Thomas' NHS Foundation Trust, London, United Kingdom., Wells P; Barts Health NHS Trust, London, United Kingdom., Vivekanandan S; Guy's & St. Thomas' NHS Foundation Trust, London, United Kingdom., Mullin AM; Cancer Research UK & University College London Cancer Trials Centre, London, United Kingdom., Hughes L; Cancer Research UK & University College London Cancer Trials Centre, London, United Kingdom., Farrelly L; Cancer Research UK & University College London Cancer Trials Centre, London, United Kingdom., Ngai Y; Cancer Research UK & University College London Cancer Trials Centre, London, United Kingdom., Counsell N; Cancer Research UK & University College London Cancer Trials Centre, London, United Kingdom.

Publikováno v: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2020 Mar 15; Vol. 106 (4), pp. 733-742. Date of Electronic Publication: 2019 Dec 03.

IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer.

Autor: Landau DB; Guy's & St. Thomas' NHS Trust, King's College London, London, United Kingdom. Electronic address: david.landau@kcl.ac.uk., Hughes L; Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom., Baker A; Clatterbridge Cancer Centre, Bebington, United Kingdom., Bates AT; Southampton General Hospital, Southampton, United Kingdom., Bayne MC; Poole Hospital, Poole, United Kingdom., Counsell N; Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom., Garcia-Alonso A; North Wales Cancer Centre, Rhyl, United Kingdom., Harden SV; Addenbrookes Hospital, Cambridge, United Kingdom., Hicks JD; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom., Hughes SR; Guy's & St. Thomas' NHS Trust, King's College London, London, United Kingdom., Illsley MC; Royal Surrey County Hospital, Guilford, United Kingdom., Khan I; Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom., Laurence V; Poole Hospital, Poole, United Kingdom., Malik Z; Clatterbridge Cancer Centre, Bebington, United Kingdom., Mayles H; Clatterbridge Cancer Centre, Bebington, United Kingdom., Mayles WPM; Clatterbridge Cancer Centre, Bebington, United Kingdom., Miles E; Mount Vernon Hospital, Middlesex, United Kingdom., Mohammed N; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom., Ngai Y; Cancer Research UK and UCL Cancer Trials Centre, London, United Kingdom., Parsons E; Mount Vernon Hospital, Middlesex, United Kingdom., Spicer J; Guy's & St. Thomas' NHS Trust, King's College London, London, United Kingdom., Wells P; St. Bartholomew's Hospital, London, United Kingdom., Wilkinson D; Mount Vernon Hospital, Middlesex, United Kingdom., Fenwick JD; University of Oxford, Oxford, United Kingdom.

Publikováno v: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2016 Aug 01; Vol. 95 (5), pp. 1367-1377. Date of Electronic Publication: 2016 Mar 28.

Imaging Tumor Response and Tumoral Heterogeneity in Non-Small Cell Lung Cancer Treated With Antiangiogenic Therapy: Comparison of the Prognostic Ability of RECIST 1.1, an Alternate Method (Crabb), and Image Heterogeneity Analysis.

Autor: Yip C; Division of Imaging Sciences and Biomedical Engineering, King's College London Departments of #Clinical Oncology **Radiology, Guy's & St Thomas' NHS Foundation Trust, London ¶Statsconsultancy Ltd, Buckinghamshire, United Kingdom †Department of Radiation Oncology, National Cancer Centre, Singapore, Singapore ‡Department of Thoracic Imaging, Hospital Calmette §Faculty of Medicine, Henri Warembourg ∥Department of Pulmonary and Thoracic Oncology, University of Lille Nord de France, Lille, France., Tacelli N, Remy-Jardin M, Scherpereel A, Cortot A, Lafitte JJ, Wallyn F, Remy J, Bassett P, Siddique M, Cook GJ, Landau DB, Goh V

Publikováno v: Journal of thoracic imaging [J Thorac Imaging] 2015 Sep; Vol. 30 (5), pp. 300-7.